Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 (Kybella) for submental fat reduction (REFINE-1)
NCT01542034Phase 3Completed
- Sponsor
- Kythera Biopharmaceuticals
- Start
- Feb 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in submental fat comparing Deoxycholic Acid Injection with Placebo (2 arms). Primary endpoints: Percentage of Participants Who Achieved a Composite 1-grade Response at 32 weeks and Percentage of Participants Who Achieved a Composite 2-grade Response at 32 weeks. Started Feb 2012; status: completed.
02
Drugs
sodium deoxycholate
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT01542034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542034.